ArticleInvestigative ophthalmology & visual science2026
Cross-Cohort Evidence of Editome Dysregulation and Cell Growth-Related IGFBP7 Recoding Driven by ADARB1 in Fuchs Endothelial Corneal Dystrophy.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Fuchs endothelial corneal dystrophy (FECD) is a degenerative disease characterized by progressive loss of corneal endothelial cells, yet the role of adenosine-to-inosine (A-to-I) RNA editing mediated by adenosine deaminases acting on RNA (ADARs) remains unelucidated. Our current study aimed to investigate the A-to-I editome in FECD and its underlying epigenetic mechanisms. Methods: Cross-cohort editome analysis was performed using corneal endothelial transcriptome datasets from two independent FECD cohorts. RNA editing was identified and compared across groups to assess differential RNA editing and its associated gene functions and pathways, followed by cell experiments and RNA-sequencing (RNA-seq) to evaluate the functional impact of selected RNA editing events. Results: Our results showed a cross-cohort reduction of average A-to-I RNA editing levels and significant upregulation of ADARB1, with 10,416 differential RNA editing events in 1138 genes in FECD compared with controls, including FECD-related genes, such as transcription factor 4. Moreover, differentially edited genes were mainly involved in cell growth and autophagy-related pathways. Notably, FECD exhibited upregulated missense RNA editing, leading to K95R recoding in insulin-like growth factor binding protein 7 (IGFBP7), positively correlated with ADARB1 expression. In vitro overexpression of ADARB1 enhanced IGFBP7 K95R editing, inhibiting cell proliferation, and inducing apoptosis via the p53-p21 axis. Transcriptome analysis further revealed that cells overexpressing recoded K95R IGFBP7 exhibited compromised expression in the mitochondrial electron transport chain. Conclusions: Our findings demonstrate substantial editome dysregulation in FECD, highlighting a role of ADARB1-mediated IGFBP7 recoding in promoting cell apoptosis and dysfunction, and providing insights into the epigenetic mechanisms underlying FECD and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.